Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Sciences of Pharmacy
Sugiastuti, Fenty
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Health Professions Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Evaluation of Total Flavonoid Content, Xanthine Oxidase Inhibition, and Uric Acid Inhibitory Activity In Vitro and In Vivo of Ethanol Extract of Sida rhombifolia Aulena, Desi Nadya; Kumala, Shirly; Abdillah, Syamsudin; Rahmat, Deni; Sugiastuti, Fenty; Indarwati, Indarwati; Fitriyani, Dwi
Sciences of Pharmacy Volume 3 Issue 3
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0303255

Abstract

Secondary metabolites content in Sida rhombifolia L. (SR) are believed to inhibit the xanthine oxidase (XO) enzyme, which is responsible for converting hypoxanthine and xanthine into uric acid. This study aimed to compare flavonoid levels, XO inhibitory activity, and the reduction of uric acid levels of sidaguri herb, stem, leaves, and root extract both in vitro and in vivo. The research results showed that the highest total flavonoid content in SR was found in the leaves, at 21.29±0.08 mg/QE/g extract. The IC50 values were as follows: roots (EESRR 1096.07±1.07 ppm), stems (EESRS 561.62±7.01 ppm), leaves (EESRL 101.84±0.63 ppm), and herbs (EESRH 104.70±3.50 ppm). EESR can inhibit the XO enzyme and has potential as an anti-hyperuricemia agent. The best total flavonoid content and IC50 values were observed in EESRL, which are 21.29±0.08 mg/QE/g and 101.84±0.63 ppm, respectively. EESRL at a dose of 400 mg/kg BW has the equivalent ability to reduce blood uric acid levels in mice when compared to the positive control group. Based on these findings, it can be concluded that EESRL has significant potential as a natural XO inhibitor and can be considered a promising candidate for the development of anti-hyperuricemia treatments.
Co-Authors . Syamsudin Aulena, Desi Nadya Dwi Fitriyani, Dwi Indarwati Indarwati RAHMAT, DENI Shirly Kumala